Literature DB >> 16441626

Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo.

D Parsad1, A J Kanwar, B Kumar.   

Abstract

BACKGROUND: Although many treatment modalities have been tried for the treatment of vitiligo, none is uniformly effective. Psoralen phototherapy (psoralen ultraviolet A (PUVA)) is established as efficacious treatment for vitiligo. Recently, narrow-band UVB (NBUVB) has been reported to be an effective and safe therapeutic option in patients with vitiligo.
OBJECTIVE: To compare the efficacy of PUVA and NBUVB in the treatment of vitiligo. DESIGN AND
SETTING: Retrospective analysis of 69 patients with vitiligo who were treated either with PUVA or NBUVB at the pigmentary clinic of the Dermatology Department of the Postgraduate Institute of Medical Education and Research, Chandigarh, India. OUTCOME MEASURES: The following variables were compared between the two groups of patients: repigmentation status, number of treatments for marked to complete repigmentation in existing lesions, appearance of new lesions or increase in size of existing lesions, adverse effect of therapy, stability of repigmentation and colour match.
RESULTS: In PUVA-treated group, 9 patients showed marked to complete repigmentation (23.6%) and 14 patients showed moderate improvement (36.8%), whereas in NBUVB-treated group, 13 patients showed marked to complete repigmentation (41.9%) and 10 patients showed moderate improvement (32.2%). A statistically significantly better stability and colour match of repigmentation with surrounding skin was seen in NBUVB-treated patients.
CONCLUSION: We showed that NBUVB is more effective than PUVA and repigmentation induced with NBUVB is statistically significantly more stable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16441626     DOI: 10.1111/j.1468-3083.2006.01413.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

1.  Rapid response of facial vitiligo to 308nm excimer laser and topical calcipotriene.

Authors:  John A Mouzakis; Stephanie Liu; George Cohen
Journal:  J Clin Aesthet Dermatol       Date:  2011-06

2.  Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VI.

Authors:  Mark G Lebwohl; Emma Guttman-Yassky; Hee J Kim; Ester Del Duca; Ana B Pavel; Giselle K Singer; Brian J Abittan; Margot A Chima; Grace Kimmel; Jennifer Bares; Danielle Baum; Matthew Gagliotti; Jordan Genece; Justin Chu
Journal:  Arch Dermatol Res       Date:  2022-03-13       Impact factor: 3.017

3.  Leucine-rich glioma inactivated 3: a novel keratinocyte-derived melanogenic cytokine in vitiligo patients.

Authors:  Azza Gaber Antar Farag; Mostafa Ahmed Hammam; Dalia Rifaat Al-Sharaky; Ghada Mohamed El-Boghdady
Journal:  An Bras Dermatol       Date:  2019-10-17       Impact factor: 1.896

Review 4.  Updates and new medical treatments for vitiligo (Review).

Authors:  David Emmanuel Kubelis-López; Natalia Aranza Zapata-Salazar; Salvador Luis Said-Fernández; Celia Nohemí Sánchez-Domínguez; Mauricio Andrés Salinas-Santander; Herminia Guadalupe Martínez-Rodríguez; Osvaldo Tomás Vázquez-Martínez; Uwe Wollina; Torello Lotti; Jorge Ocampo-Candiani
Journal:  Exp Ther Med       Date:  2021-05-25       Impact factor: 2.447

5.  Correlation of Vitamin D Levels with Pigmentation in Vitiligo Patients Treated with NBUVB Therapy.

Authors:  Manu Sehrawat; Tarlok Chand Arora; Amrita Chauhan; Hemanta Kumar Kar; Amitabh Poonia; Vijayeeta Jairath
Journal:  ISRN Dermatol       Date:  2014-03-23

Review 6.  Pharmacological Activities of Psoralidin: A Comprehensive Review of the Molecular Mechanisms of Action.

Authors:  Javad Sharifi-Rad; Senem Kamiloglu; Balakyz Yeskaliyeva; Ahmet Beyatli; Mary Angelia Alfred; Bahare Salehi; Daniela Calina; Anca Oana Docea; Muhammad Imran; Nanjangud Venaktesh Anil Kumar; Maria Eugenia Romero-Román; Alfred Maroyi; Miquel Martorell
Journal:  Front Pharmacol       Date:  2020-10-22       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.